Barclays Maintains Equal-Weight on PTC Therapeutics, Lowers Price Target to $44
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang has maintained an Equal-Weight rating on PTC Therapeutics (NASDAQ:PTCT) but lowered the price target from $48 to $44.
August 04, 2023 | 3:54 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
PTC Therapeutics' price target has been lowered from $48 to $44 by Barclays, while maintaining an Equal-Weight rating.
The lowering of the price target by Barclays indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100